bimagrumab tirzepatide clinical trial Update from #ADA2025 : 🧬 Bimagrumab Targets Activin Pathway in Obesity – Dual Action Molecule 👨‍⚕️ #ADA2025 #Obesity #WeightLoss 🔹 What is Bimagrumab? A monoclonal antibody that blocks activin type II The BELIEVE Trial: Rethinking What

Individual pain sensitivity varies based on skin thickness, needle anxiety, injection speed, and muscle tension at the injection site

Pharmacology & Therapeutics, 227, 107863

I kept telling doctors something felt off, but no one really listened

Following acute infection with Borrelia burgdorferi (Bb), a chronic inflammatory disease can emerge which targets joints or the CNS in the absence of residual bacterial infection

A recent analysis of the latest data did not find "evidence that use of these medicines causes suicidal thoughts or actions." However, the researchers added that further study is needed on semaglutide's effects on people who are suffering from depression or other serious mental illness

Related Stories Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations AI text analysis reveals hidden mental health signs in emergency call takers and dispatchers GLP-1 receptor activation linked to lower depression and bipolar disorder odds Individuals receiving semaglutide and tirzepatide generally had lower hazards of several recorded neuropsychiatric diagnoses when compared to bariatric surgery recipients